Beneficial effect of cinacalcet in a child with familial hypocalciuric hypercalcemia.
We describe a child with familial hypocalciuric hypercalcemia (FHH) in whom the hypercalcemia seemed to interfere with tissue healing after tympanoplasty. Consequently, he was placed on cinacalcet (30 mg/day), changed after 2 weeks to 60 mg/day. The treatment resulted in a decrease in serum parathyroid hormone (PTH) from 148 to 32 pg/mL (normal 7-75) and ionized calcium from 1.48 to 1.23 mmol/L (1.13-1.34), as well as successful healing of the revised surgical scar. Over the 12-month treatment period no complications were noted. We conclude that cinacalcet may be considered a new, and currently the only, tool in treating children with symptomatic FHH.
Alon
Uri S
US
Section of Pediatric Nephrology, Bone and Mineral Disorders Clinic, Children's Mercy Hospitals and Clinics, University of Missouri at Kansas City, 2401 Gillham Road, Kansas City, MI 64108, USA. ualon@cmh.edu
VandeVoorde
René G
RG
D015415:Biomarkers / Q000097:blood / Q000652:urine; D002118:Calcium / Q000097:blood / Q000652:urine; D002648:Child; D000069449:Cinacalcet; D020022:Genetic Predisposition to Disease; D006801:Humans; D006934:Hypercalcemia / Q000097:blood / Q000188:drug therapy* / Q000235:genetics / Q000652:urine; D008297:Male; D009154:Mutation; D009281:Naphthalenes / Q000627:therapeutic use*; D010281:Parathyroid Hormone / Q000097:blood; D010375:Pedigree; D044169:Receptors, Calcium-Sensing / Q000235:genetics; D013997:Time Factors; D016896:Treatment Outcome; D014433:Tympanoplasty; D014945:Wound Healing / Q000187:drug effects
D015415:Biomarkers; C095550:CASR protein, human; D009281:Naphthalenes; C470125:PTH protein, human; D010281:Parathyroid Hormone; D044169:Receptors, Calcium-Sensing; D002118:Calcium; D000069449:Cinacalcet